Summary of change from baseline at six weeks and 26 weeks for main outcomes plus comparative statistics

Mean difference (95%, CI), P value Rivastigmine Quetiapine Placebo Rivastigmine v placebo Quetiapine v placebo Rivastigmine v quetiapine Mean (SD) change in CMAI from baseline:     To week 6 -5.1 (16.3) (n=24) -4.0 (15.4) (n=27) -6.2 (17.6) (n=29) 4.1 (-4.2 to 12.3), P=0.3 3.5 (-3.7 to 10.8), P=0.3 0.29 (-8.0 to 8.6), P=0.9     To week 26 -10.8 (19.9) (n=24) -8.1 (12.7) (n=27) -9.0 (16.5) (n=30) 2.2 (-5.3 to 9.7), P=0.6 2.0 (-4.2 to 8.3); P=0.5 -0.52 (-8.0 to 6.9), P=0.9 Mean (SD) change in SIB from baseline:     To week 6 1.8 (14.7) (n=14) -10.5 (14.8) (n=14) 3.2 (15.1) (n=18) -3.5 (-13.1 to 6.2), P=0.5 -14.6 (-25.3 to -4.0), P=0.009 12.0 (0.76 to 23.2), P=0.04     To week 26 -3.1 (20.6) (n=15) -11.3 (15.6) (n=15) 3.3 (17.4) (n=19) -7.5 (-21.0 to 6.0), P=0.3 -15.4 (-27.0 to -3.8), P=0.01 8.3 (-5.6 to 22.3), P=0.2

CMAI=Cohen-Mansfield agitation inventory; SIB=severe impairment battery.